Athena Athena

X

Find the latest Drugs in Development and Pipeline Prospector News of Codexis.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Codexis
United_States_of_America Flag
Country
Country
U.S.A
Address
Address
200 Penobscot Drive, Redwood City, CA 94063
Telephone
Telephone
1 650 421 8100

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

Through agreement, Nestlé Health Science will be solely responsible for the continued development and commercialization of CDX-7108, an investigational therapy for the potential treatment of exocrine pancreatic insufficiency (EPI).


Lead Product(s): CDX-7108

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CDX-7108

Highest Development Status: Phase IProduct Type: Small molecule

Recipient: Nestle Health Sciences SA

Deal Size: $50.0 million Upfront Cash: $5.0 million

Deal Type: Agreement December 27, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

CDX-7108 is an orally administered therapeutic lipase enzyme variant specifically engineered to overcome the limitations of existing pancreatic enzyme replacement therapy (PERT). PERT is the main treatment for exocrine pancreatic insufficiency (EPI).


Lead Product(s): CDX-7108

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CDX-7108

Highest Development Status: Phase IProduct Type: Large molecule

Partner/Sponsor/Collaborator: Nestle Health Sciences SA

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 23, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The unique enzyme is an important element in the manufacture of PAXLOVID™ (ritonavir) and plays a role in supporting the efforts to ensure rapid availability of this COVID-19 oral treatment to people around the world.


Lead Product(s): Nirmatrelvir,Ritonavir

Therapeutic Area: Infections and Infectious Diseases Product Name: Paxlovid

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Pfizer Inc

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement July 14, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Pre-clinical data highlights enzyme variants engineered with Codexis’ CodeEvolver® platform to offer potentially improved efficacy as compared to current enzymes when administered as transgenes in gene therapies for Hemophilia A, Fabry Disease, and Pompe Disease.


Lead Product(s): CDX-6316

Therapeutic Area: Genetic Disease Product Name: CDX-6316

Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Takeda Pharmaceutical

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 16, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Two poster to be presentated highlighting three of the Company’s gene therapy programs using directed evolution to potentially improve treatment options for Hemophilia A and lysosomal storage diseases.


Lead Product(s): Undisclosed

Therapeutic Area: Genetic Disease Product Name: Undisclosed

Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 02, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

CDX-6512, a gastrointestinal-stable methionine-gamma-lyase as a potential orally-administered enzyme therapy for homocystinuria, which demonstrated up to a 45% suppression in serum total homocysteine.


Lead Product(s): CDX-6512

Therapeutic Area: Genetic Disease Product Name: CDX-6512

Highest Development Status: PreclinicalProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 22, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

CDX-7108 is a lipase variant specifically engineered to overcome the limitations of traditional pancreatic enzyme replacement therapy (PERT) deficiencies. CDX-7108 is highly stable to the acidic conditions in the stomach and resistant to proteases in the upper intestines.


Lead Product(s): CDX-7108

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CDX-7108

Highest Development Status: Phase IProduct Type: Small molecule

Partner/Sponsor/Collaborator: Nestle Health Sciences SA

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 03, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Under a research and development agreement, Codexis and Merck leveraged Codexis’ CodeEvolver® enzyme engineering platform technology to design a novel, proprietary enzyme to serve as a biocatalyst in the sitagliptin manufacturing process.


Lead Product(s): Sitagliptin Phosphate

Therapeutic Area: Endocrinology Product Name: Januvia

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Merck & Co

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement September 09, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

This milestone marks the advancement of the commercialization of an enzyme, generated using CodeEvolver under the licensing agreement, that is engineered to improve a key step in the manufacturing process for a currently undisclosed drug.


Lead Product(s): Undisclosed

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: UndisclosedProduct Type: Undisclosed

Partner/Sponsor/Collaborator: GSK

Deal Size: $25.0 million Upfront Cash: $6.0 million

Deal Type: Collaboration July 07, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The companies’ new agreement will advance the development of CDX-7108, the lead candidate for a potential treatment of a GI disorder.


Lead Product(s): CDX-7108

Therapeutic Area: Gastroenterology Product Name: Undisclosed

Highest Development Status: DiscoveryProduct Type: Undisclosed

Partner/Sponsor/Collaborator: Nestle Health Sciences SA

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration January 10, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY